The lack of sufficient NK cells in the HL tumour microenvironment may explain the failure of naked mAbs targeting CD30, the most prominent tumor antigen of malignant HL cells, to achieve positive outcomes in phase I–II clinical trials13–15. Here, TNFRSF8 is linked to neoplasm.